Dynasil Corporation of America(NASDAQ:DYSL) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during After-Market on Feb 13, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $9.143M. Analysts estimated a revenue of $52.990M. The revenues were -82.75% below the estimates. Earnings per share were $0.17.
Dynasil Corporation of America (DYSL) made into the market gainers list on Wednesdays trading session with the shares advancing 2.50% or 0.03 points. Due to strong positive momentum, the stock ended at $1.23, which is also near the day’s high of $1.26. The stock began the session at $1.26 and the volume stood at 1,56,302 shares. The 52-week high of the shares is $2.01 and the 52 week low is $0.8909. The company has a current market capitalization of $21 M and it has 1,69,60,329 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Aug 2, 2016, David Kronfeld (director) sold 5,869 shares at $1.42 per share price.
Dynasil Corporation of America (Dynasil) develops and manufactures optical detection and analysis technology and components for the homeland security medical and industrial markets. It is commercializing various products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing. Dynasil operates through four segments: Contract Research Optics Instruments and Biomedical. The Company operates through four segments: Contract Research Optics Instruments and Biomedical. The Contract Research segment consists of the Radiation Monitoring Devices Inc. (RMD) business unit. The Optics segment encompasses four business units: Dynasil Fused Silica Optometrics Hilger Crystals and Evaporated Metal Films. The Instruments segment manufactures precision instrumentation for medical and commercial applications. The Biomedical segment operates through Dynasil Biomedical Corporation.